News Lonza builds its ADC capacity with Synaffix takeover Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.